Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
Want to see OTLC full AI Analyst Report?
OTLC Stock Chart & Stats
$0.08
>-$0.01(-12.62%)
At close: 4:00 PM EST
$0.08
>-$0.01(-12.62%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume643.67K
Average Volume (3M)410.07K
Market Cap
$16.70M
Enterprise Value$16.18T
Total Cash (Recent Filing)$88.86B
Total Debt (Recent Filing)$16.27T
Price to Earnings (P/E)<0.1
Beta-0.21
Next Earnings
May 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.59
Shares Outstanding444,197,020
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap969.35K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.51M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetA materially stronger 2025 capital structure—very large equity versus modest debt—reduces near-term leverage risk and increases financial flexibility. This durable strengthening supports continued R&D, JV execution, and partnership negotiations without immediate reliance on dilutive financing.
Clinical And Platform AdvancementProgression from Phase 1 to Phase 2/3 and multiple Deciparticle candidates diversifies clinical risk and concretely de-risks the pipeline. Over months this raises the probability of value-inflection events, builds program-level credibility, and supports longer-term partnership or licensing opportunities.
AI-driven GMP Automation PartnershipA formal commercialization JV for AI-enabled GMP robotics creates a structural revenue diversification path beyond drug development. If deployed, recurring licensing, manufacturing services, and differentiated GMP automation can scale operations, reduce COGS, and create durable competitive advantage.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicate the company cannot fund operations internally. Over the medium term this necessitates repeat external financing, constrains R&D pacing, and elevates execution risk for clinical programs absent sustainable cash generation.
Earnings Quality Driven By Non-cash UpliftThe large 2025 profit stems from a one-time non-cash fair-value gain that does not improve operating cash flow or recurring profitability. Reliance on such accounting gains reduces earnings visibility and makes reported profitability a poor indicator of underlying business health over the next several quarters.
Ongoing Financing And Dilution RiskFrequent use of secured convertible notes, attached warrants, and CEO equity tied to capital milestones signals continued cash needs and potential dilution. Such financing structures preserve runway short term but can materially dilute shareholders and shift management focus to capital structure fixes.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $16.70M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is May 25, 2026 which is in 20 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Oncotelic Therapeutics released its earnings results on Apr 16, 2026. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of N/A by $0.59.
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 444,197,020 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Oncotelic Therapeutics reported an EPS of $0.59 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.882%.
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---